These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26279333)

  • 1. Long-term enzyme-replacement therapy (ERT) with alglucosidase alfa: Evolution of two siblings with juvenile late-onset Pompe disease.
    Rafael Bretón Martínez J; Martínez AC
    J Neurol Sci; 2015 Nov; 358(1-2):459-60. PubMed ID: 26279333
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.
    Case LE; Bjartmar C; Morgan C; Casey R; Charrow J; Clancy JP; Dasouki M; DeArmey S; Nedd K; Nevins M; Peters H; Phillips D; Spigelman Z; Tifft C; Kishnani PS
    Neuromuscul Disord; 2015 Apr; 25(4):321-32. PubMed ID: 25617983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.
    van der Ploeg A; Carlier PG; Carlier RY; Kissel JT; Schoser B; Wenninger S; Pestronk A; Barohn RJ; Dimachkie MM; Goker-Alpan O; Mozaffar T; Pena LD; Simmons Z; Straub V; Guglieri M; Young P; Boentert M; Baudin PY; Wens S; Shafi R; Bjartmar C; Thurberg BL
    Mol Genet Metab; 2016 Sep; 119(1-2):115-23. PubMed ID: 27473031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pompe disease: early diagnosis and early treatment make a difference.
    Chien YH; Hwu WL; Lee NC
    Pediatr Neonatol; 2013 Aug; 54(4):219-27. PubMed ID: 23632029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial.
    Strothotte S; Strigl-Pill N; Grunert B; Kornblum C; Eger K; Wessig C; Deschauer M; Breunig F; Glocker FX; Vielhaber S; Brejova A; Hilz M; Reiners K; Müller-Felber W; Mengel E; Spranger M; Schoser B
    J Neurol; 2010 Jan; 257(1):91-7. PubMed ID: 19649685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-frequency enzyme replacement therapy in late-onset Pompe disease.
    Lin DS; Chiang MF; Ho CS; Hsiao CD; Lin CY; Wang NL; Chuang CK; Huang YW; Chang PC; Liu HL
    Muscle Nerve; 2013 Apr; 47(4):612-3. PubMed ID: 23322609
    [No Abstract]   [Full Text] [Related]  

  • 7. Alglucosidase alfa: new drug. Pompe disease: a short-term benefit.
    Prescrire Int; 2007 Dec; 16(92):240-1. PubMed ID: 18092404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa.
    de Vries JM; van der Beek NA; Kroos MA; Ozkan L; van Doorn PA; Richards SM; Sung CC; Brugma JD; Zandbergen AA; van der Ploeg AT; Reuser AJ
    Mol Genet Metab; 2010 Dec; 101(4):338-45. PubMed ID: 20826098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease.
    Papadopoulos C; Orlikowski D; Prigent H; Lacour A; Tard C; Furby A; Praline J; Solé G; Hogrel JY; De Antonio M; Semplicini C; Deibener-Kaminsky J; Kaminsky P; Eymard B; Taouagh N; Perniconi B; Hamroun D; Laforêt P;
    Mol Genet Metab; 2017 Sep; 122(1-2):80-85. PubMed ID: 28648663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative computed tomography for enzyme replacement therapy in Pompe disease.
    Yonee C; Toyoshima M; Young SP; Maruyama S; Higuchi I; Narita A; Maegaki Y; Nanba E; Ohno K; Kawano Y
    Brain Dev; 2012 Nov; 34(10):834-9. PubMed ID: 22521436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation.
    Desai AK; Walters CK; Cope HL; Kazi ZB; DeArmey SM; Kishnani PS
    Mol Genet Metab; 2018 Feb; 123(2):92-96. PubMed ID: 29289479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naïve and alglucosidase alfa-treated patients with late-onset Pompe disease: A phase 1, open-label, multicenter, multinational, ascending dose study.
    Pena LDM; Barohn RJ; Byrne BJ; Desnuelle C; Goker-Alpan O; Ladha S; Laforêt P; Mengel KE; Pestronk A; Pouget J; Schoser B; Straub V; Trivedi J; Van Damme P; Vissing J; Young P; Kacena K; Shafi R; Thurberg BL; Culm-Merdek K; van der Ploeg AT;
    Neuromuscul Disord; 2019 Mar; 29(3):167-186. PubMed ID: 30770310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement with ongoing Enzyme Replacement Therapy in advanced late-onset Pompe disease: a case study.
    Case LE; Koeberl DD; Young SP; Bali D; DeArmey SM; Mackey J; Kishnani PS
    Mol Genet Metab; 2008 Dec; 95(4):233-5. PubMed ID: 18930676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved efficacy of a next-generation ERT in murine Pompe disease.
    Xu S; Lun Y; Frascella M; Garcia A; Soska R; Nair A; Ponery AS; Schilling A; Feng J; Tuske S; Valle MCD; Martina JA; Ralston E; Gotschall R; Valenzano KJ; Puertollano R; Do HV; Raben N; Khanna R
    JCI Insight; 2019 Mar; 4(5):. PubMed ID: 30843882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in forced vital capacity over ≤ 13 years among patients with late-onset Pompe disease treated with alglucosidase alfa: new modeling of real-world data from the Pompe Registry.
    Berger KI; Chien YH; Dubrovsky A; Kishnani PS; Llerena JC; Neilan E; Roberts M; Sheng B; Batista JL; Periquet M; Wilson KM; van der Ploeg AT
    J Neurol; 2024 Aug; 271(8):5433-5446. PubMed ID: 38896264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease.
    Kanters TA; van der Ploeg AT; Kruijshaar ME; Rizopoulos D; Redekop WK; Rutten-van Mӧlken MPMH; Hakkaart-van Roijen L
    Orphanet J Rare Dis; 2017 Dec; 12(1):179. PubMed ID: 29237491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Open-label extension study following the Late-Onset Treatment Study (LOTS) of alglucosidase alfa.
    van der Ploeg AT; Barohn R; Carlson L; Charrow J; Clemens PR; Hopkin RJ; Kishnani PS; Laforêt P; Morgan C; Nations S; Pestronk A; Plotkin H; Rosenbloom BE; Sims KB; Tsao E
    Mol Genet Metab; 2012 Nov; 107(3):456-61. PubMed ID: 23031366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infantile Pompe disease: clinical and genetic characteristics with an experience of enzyme replacement therapy.
    Cho A; Kim SJ; Lim BC; Hwang H; Park JD; Kim GB; Jin DK; Lee J; Ki CS; Kim KJ; Hwang YS; Chae JH
    J Child Neurol; 2012 Mar; 27(3):319-24. PubMed ID: 21940687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unwarranted, long term, alglucosidase alfa enzyme replacement therapy in two non-Pompe disease patients.
    Karam C; Ragole T; Moshe-Lilie O; Chahin N
    Clin Neurol Neurosurg; 2020 Sep; 196():106048. PubMed ID: 32623214
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry.
    Semplicini C; De Antonio M; Taouagh N; Béhin A; Bouhour F; Echaniz-Laguna A; Magot A; Nadaj-Pakleza A; Orlikowski D; Sacconi S; Salort-Campana E; Solé G; Tard C; Zagnoli F; Hogrel JY; Hamroun D; Laforêt P;
    J Inherit Metab Dis; 2020 Nov; 43(6):1219-1231. PubMed ID: 32515844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.